Levofloxacin 0.5 ophthalmic solution: A review of its use in the treatment of external ocular infections and in intraocular surgery

Drugs

Volumn 69, Issue 9, 2009, Pages 1267-1286

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; EYE DROPS; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MOXIFLOXACIN; NEOMYCIN; NORFLOXACIN; OFLOXACIN; OFTAQUIX; POLYMYXIN; POVIDONE IODINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFACETAMIDE; TOSUFLOXACIN; UNCLASSIFIED DRUG;

ABNORMAL SENSATION; ACCOMMODATION; ALLERGIC CONJUNCTIVITIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIUM CULTURE; BLEPHARITIS; BLEPHAROSPASM; BURNING SENSATION; CATARACT EXTRACTION; CATARRHAL CONJUNCTIVITIS; CHALAZION; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTACT DERMATITIS; CORNEA DISEASE; CORNEA EROSION; CORNEA ULCER; DACRYOCYSTITIS; DIARRHEA; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG UPTAKE; DYSGEUSIA; ENDOPHTHALMITIS; ERADICATION THERAPY; EYE CONGESTION; EYE DISCOMFORT; EYE DISEASE; EYE INFECTION; EYE IRRITATION; EYE PAIN; EYELID EDEMA; EYELID ERYTHEMA; EYELID PAIN; EYELID PRURITUS; HAND PARESTHESIA; HORDEOLUM; HUMAN; INCIDENCE; INJECTION SITE PAIN; KERATITIS; MAXIMUM ALLOWABLE CONCENTRATION; NAUSEA; OCULAR PRURITUS; ORAL NUMBNESS; ORAL PARESTHESIA; PARESTHESIA; PHOTOPHOBIA; POSTMARKETING SURVEILLANCE; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRESCRIPTION; PROPHYLAXIS; PUNCTATE KERATITIS; RECOMMENDED DRUG DOSE; REVIEW; RHINITIS; SIDE EFFECT; TARSITIS; TREATMENT OUTCOME; URTICARIA; VISUAL DISORDER;

ANTI-BACTERIAL AGENTS; CONJUNCTIVITIS; DRUG RESISTANCE, BACTERIAL; EYE INFECTIONS; HUMANS; OFLOXACIN; OPHTHALMOLOGIC SURGICAL PROCEDURES; POSTOPERATIVE COMPLICATIONS; PRODUCT SURVEILLANCE, POSTMARKETING;

BACTERIA (MICROORGANISMS);

EID: 67649345664     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-200969090-00009     Document Type: Review

References (59)

1. DeCroos FC, Afshari NA. Perioperative antibiotics and anti-inflammatory agents in cataract surgery. Curr Opin Ophthalmol 2008; 19: 22-6
2. Rose P. Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin Pharmacother 2007; 8 (12): 1903-21
3. Santen. Quixin® (levofloxacin ophthalmic solution) 0.5%: prescribing information [online]. Available from URL: http://www.quixin.com/ [Accessed 2009 Mar 27]
4. Santen Pharmaceuticals Co., Ltd. Cravit® ophthalmic solution: prescribing information. Osaka: Santen Pharmaceuticals Co., Ltd, 2005 Oct
5. Santen. Products in Europe [online].Available from URL: http://www.santen.eu/index/products.html [Accessed 2009 Apr 8]
6. Drlica K. Mechanism of fluoroquinolone action. Curr Opin Microbiol 1999 Oct; 2 (5): 504-8
7. Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008 Jun; 145 (6): 951-8
8. Yamada M, Hatou S, Yoshida J. In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin. Eye Contact Lens 2008 Mar; 34 (2): 109-12
9. Matsuzaki K, Watabe E, Shikano M, et al. Susceptibility of ocular infection isolates to levofloxacin and other antimicrobial drugs [in Japanese]. Atarashii Ganka 2004; 21 (11): 1539-46
10. Kobayashi I, Matsuzaki K, Shitou K, et al. Surveillance of ocular infection isolate susceptibility to levofloxacin and other antimicrobial drugs [in Japanese]. Atarashii Ganka 2006; 23 (2): 237-43
11. Shimomura Y, Ohashi Y, Matsumoto K, et al. Phase III comparative study of moxifloxacin ophthalmic solution in bacterial conjunctivitis (multi center, double-masked study) [in Japanese]. Atarashii Ganka 2007; 24 (10): 1381-94
12. Eguchi H, Kuwahara T, Miyamoto T, et al. High-level fluoroquinolone resistance in ophthalmic clinical isolates belonging to the species Corynebacterium macginleyi. J Clin Microbiol 2008 Feb; 46 (2): 527-32
13. Graves A, Henry M, O'Brien TP, et al. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones. Cornea 2001 Apr; 20 (3): 301-5
14. Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs 2008; 68 (4): 535-65
15. Hoshi S, Kikuchi K, Sasaki T, et al. Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolonesensitive methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2008 Aug; 52 (8): 2970-3
16. FukudaM, Sasaki H. Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions. Curr Med Res Opin 2008 Dec; 24 (12): 3479-86
17. Sasaki K, Mitsui Y, Fukuda M, et al. Intraocular penetration mode of five fluoroquinolone ophthalmic solutions evaluated by the newly proposed parameter of AQCmax [in Japanese]. Atarashii Ganka 1995; 12 (5): 787-90
18. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol 2004 Mar; 49 Suppl. 2: S79-83
19. Iihara H, Suzuki T, Kawamura Y, et al. Emerging multiple mutations and high-level fluoroquinolone resistance in methicillin-resistant Staphylococcus aureus isolated from ocular infections. Diagn Microbiol Infect Dis 2006 Nov; 56 (3): 297-303
20. Yamada M, Yoshida J, Hatou S, et al. Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones. Br J Ophthalmol 2008 Jun; 92 (6): 848-51
21. Hori Y, Maeda N, Sakamoto M, et al. Fluoroquinoloneresistant bacteria and methicillin-resistant Staphylococci from normal preoperative conjunctiva [letter]. J Cataract Refract Surg 2008 Apr; 34 (4): 711-2
22. Park SH, Lim J-A, Choi J-S, et al. The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics. Cornea 2009 Jan; 28 (1): 68-72
23. Kaji Y, Oshika T. Fluoroquinolone toxicities to corneal epithelial cells [in Japanese]. Atarashii Ganka 2007; 24 (9): 1229-32
24. Sakurai M, Hatou S, Mochizuki H, et al. In vitro effects of fluoroquinolones on corneal epithelial cells and keratocytes [in Japanese]. Atarashii Ganka 2006; 23 (9): 1209-12
25. Kawahara M, Nakamura M, Fuji S, et al. Comparative studies of corneal epithelial wound healing effects and ocular pharmacokinetics of Cravit® and Tarivid® ophthalmic solutions after corneal debridement in rabbits [in Japanese]. Atarashii Ganka 2002; 19 (6): 793-6
26. Koch H-R, Kulus SC, Roessler M, et al. Corneal penetration of fluoroquinolones: aqueous humor concentrations after topical application of levofloxacin 0.5% and ofloxacin 0.3% eyedrops. J Cataract Refract Surg 2005 Jul; 31 (7): 1377-85
27. Raizman MB, Rubin JM, Graves AL, et al. Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers. Clin Ther 2002 Sep; 24 (9): 1439-50
28. Sakamoto H, Sakamoto M, Hata Y, et al. Aqueous and vitreous penetration of levofloxacin after topical and/or oral administration. Eur J Ophthalmol 2007; 17 (3): 372-6
29. Kawazu K, Midori Y, Ota A. Cultured rabbit corneal epithelium elicits levofloxacin absorption and secretion. J Pharm Pharmacol 1999 Jul; 51 (7): 791-6
30. Kawazu K,Midori Y, ShionoH, et al. Characterization of the carrier-mediated transport of levofloxacin, a fluoroquinolone antimicrobial agent, in rabbit cornea. J Pharma Pharmacol 1999 Jul; 51 (7): 797-801
31. Wagner RS, Abelson MB, Shapiro A, et al. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue [letter]. Arch Ophthalmol 2005 Sep; 123 (9): 1282-3
32. Healy DP, Holland EJ, Nordlund ML, et al. Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration. Cornea 2004 Apr; 23 (3): 255-63
33. Cantor LB, WuDunn D, Yung CW, et al. Ocular penetration of levofloxacin, ofloxacin and ciprofloxacin in eyes with functioning filtering blebs: investigator masked, randomised clinical trial. Br J Ophthalmol 2008 Mar; 92 (3): 345-7
34. Colin J, Simonpoli S, Geldsetzer K, et al. Corneal penetration of levofloxacin into the human aqueous humour: a comparison with ciprofloxacin. Acta Ophthalmol Scand 2003 Dec; 81 (6): 611-3
35. Kitano S, Miyanaga Y, Ohno S, et al. Clinical evaluation of TN-3262a in bacterial conjunctivitis: a multicenter, doublemasked, 0.5% levofloxacin ophthalmic solution control study. Atarashii Ganka 2006; 23 Suppl.: 95-110
36. Schwab IR, Friedlaender M, McCulley J, et al. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 2003 Mar; 110 (3): 457-65
37. Hwang DG, Schanzlin DJ, Rotberg MH, et al. A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol 2003 Aug; 87 (8): 1004-9
38. Szaflik J, Szaflik JP, Kamińska A, et al. Clinical and microbiological efficacy of levofloxacin administered three times a day for the treatment of bacterial conjunctivitis. Eur J Ophthalmol 2009; 19 (1): 1-9
39. Ohashi H, Shimomura Y. Clinical efficacy of 0.5% levofloxacin eyedrops for bacterial conjunctivitis in newborns, infants and children [in Japanese]. Atarashii Ganka 2002; 19 (5): 645-8
40. Lichtenstein SJ, Rinehart M. and the Levofloxacin Bacterial Conjunctivitis Study Group. Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients. J AAPOS 2003 Oct; 7 (5): 317-24
41. Usui M. Clinical evaluation of levofloxacin ophthalmic solution: phase III open label trial [in Japanese]. Atarashii Ganka 1997; 14 (7): 1113-8
42. Usui M. Clinical evaluation of levofloxacin ophthalmic solution: a multicenter phase III double-masked clinical trial [in Japanese]. Atarashii Ganka 1997; 14 (4): 641-8
43. Kanda Y, Kayama T, Okamoto S, et al. A post-marketing surveillance of 0.5% levofloxacin ophthalmic solution for external ocular infections [in Japanese]. Rinsho Ganka 2008; 62 (13): 2007-17
44. Usui M. Effect of levofloxacin ophthalmic solution on preoperative sterilization [in Japanese]. Atarashii Ganka 1997; 14 (6): 953-6
45. Inoue Y, Usui M, Ohashi Y. Preoperative disinfection of the conjunctival sac with antibiotics and iodine compounds: a prospective randomized multicenter study. Jpn J Ophthalmol 2008; 52 (3): 151-61
46. Mino de Kaspar H, Kreutzer TC, Aguirre-Romo I, et al. A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora. Am J Ophthalmol 2008 Jan; 145 (1): 136-42
47. ESCRS Endophthalmitis Study Group. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg 2007 Jun; 33 (6): 978-88
48. Høvding G. Acute bacterial conjunctivitis. Acta Ophthalmol 2008; 86: 5-17
49. Sheikh A, Hurwitz . Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2006 Apr 19; (2): CD001211
50. American Academy of Ophthalmology. Preferred practice pattern: conjunctivitis [online]. Available from URL: http://one.aao.org/asset.axd?id= 70977954-f688-41e3-a009-d2beb86765a9 [Accessed 2009 Mar 25]
51. American Academy of Ophthalmology. Preferred practice pattern: bacterial keratitis [online]. Available from URL: http://one.aao.org/asset.axd?id= 52f784ae-e2b7-4135-9671-4b4eec1dde99 [Accessed 2009 Apr 9]
52. Mueller JB, McStay CM. Ocular infection and inflammation. Emerg Med Clin N Am 2008; 26: 57-72
53. Chalita MR, Höfling-Lima AL, Paranhos AJ. Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol 2004 Jan; 137 (1): 43-51
54. Tarabishy AB, Jeng BH. Bacterial conjunctivitis: a review for internists. Cleve Clin J Med 2008 Jul; 75 (7): 507-12
55. Epstein SP, Bottone EJ, Asbell PA. Susceptibility testing of clinical isolates of Pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating Pseudomonas ocular infections. Eye Contact Lens 2006 Sep; 32 (5): 240-4
56. Patel PB, Diaz MCG, Bennett JE, et al. Clinical features of bacterial conjunctivitis in children. Acad Emerg Med 2007 Jan; 14 (1): 1-5
57. Gore DM, Angunawela RI, Little BC. United Kingdom survey of antibiotic prophylaxis practice after publication of the ESCRS endophthalmitis study. J Cataract Refract Surg 2009 Apr; 35: 770-3
58. Chang DF, Braga-Mele R, Mamalis N, et al. Prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2007 ASCRS member survey. J Cataract Refract Surg 2007 Oct; 33: 1801-5
59. Everitt HA, Little PS, Smith PWF. A randomised controlled trial of management strategies for acute infective conjunctivitis in general practice. Br Med J 2006 Aug 12; 333 (7563): 321